tbuckley/cabot-search huggingface dataset:
AB1450-HPR Comparison of biopsychosocial status of rheumatoid arthritis and fibromyalgia patients
Authors: F.B Oflaz, M. Zahidinova, G. Arın, N.B. Karaca, S. Apraş Bilgen, E. Ünal
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatic diseases have biopsychosocial effects on individiuals.<sup>1</sup> This affection includes the combination of anxiety, depression, and participation in daily living activities. It can be thought that individuals can be affected from different diseases in different ways. <h3>Objectives</h3> The aim of this study is to compare the biopsychosocial status of patients with Rheumatoid Arthritis (RA) and Fibromyalgia (FMS). <h3>Methods</h3> Individuals diagnosed with Rheumatoid Arthritis (RA) and Fibromyalgia (FMS) who applied to the Rheumatology Department of the Medical Faculty of Hacettepe University were included in the study. After the demographic characteristics of the individuals were recorded; daily living activities were assessed with the Health Assessment Questionnaire (HAQ), quality of life with Short Form 36 (SF-36) scale, anxiety and depression levels with Hospital Anxiety and Depression Scale (HADS) and disease related biopsychosocial status with the Cognitive Exercise Therapy Approach Scale (BETY) which is a newly developed scale in rheumatic patients (the authors request that the abbreviation stay as "BETY" as the original in Turkish).<sup>2</sup> <h3>Results</h3> 120 RA and 99 FMS patients were included in the study. The scores of individuals on scales are shown in Table 1. When analysed in terms of differences according to RA and FMS, the anxiety and depression scores of the HADS scale and the SF-36 quality of life scale of the individuals were found to differ between the Physical Functioning, Social Functioning, General Mental Health, Role Limitations Due to Emotional Problems, Vitality Energy or Fatigue and General Health Perception subparametric scores. <h3>Conclusions</h3> Physical function, mental health, emotional role strength, energy vitality and general health perception, anxiety and depression levels in RA patients were found to be better than FMS patients. The activities of daily living were thought to be unaffected by the changing parameters of pain and biopsychosocial status. <h3>References</h3> [1] van Middendorp H, Evers AWM. The role of psychological factors in inflammatory rheumatic diseases: From burden to tailored treatment. Best Practice &amp; Research Clinical Rheumatology. 2016;30(5):932–45. [2] Ünal E, Arin G, Karaca Nb, Kiraz S, Akdoğan A, Kalyoncu U, et al. Romatizmalı hastalar için bir yaşam kalitesi ölçeğinin geliştirilmesi: madde havuzunun oluşturulması. Journal of Exercise Therapy and Rehabilitation. 2017;4(2):67–75. <h3>Disclosure of Interest</h3> None declared
Abstract 14458: Recent Population-Based Trends in AHA Cardiovascular Health Metrics Using Electronic Health Records—Opportunities and Targets for Improvement
Authors: Alan S Go, Thomas Leong, Sue Hee Sung, Marc Jaffe, Jamal S Rana, Stephen Sidney, Joan C Lo
Journal: Circulation (2017)

Introduction: Improved cardiovascular disease (CVD) population-level prevention efforts are needed. American Heart Association’s (AHA) Life Simple 7 can be used to track cardiovascular health using...
SAT0393 Development of a score for the diagnosis of infectious arthritis in difficult to puncture joints
Authors: C.A. Guillen-Astete, B. Blanco Cáceres
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In previous studies, we have demonstrated the benefit of the determination of serum procalcitonin in the diagnostic discrimination between gouty and an infectious monoarthritis. On the other hand, the utility of this analyte has been suggested in the diagnostic study of monoarthritis in which the obtention of joint fluid for lab analysis is difficult or impossible in the immediate term. <h3>Objectives</h3> The objective of this study is to perform the validation of a score to determine the diagnosis of Native Joint Septic Arthritis (ASAN) in difficult to puncture joints. <h3>Methods</h3> A logistic regression study was conducted using 37 cases of ASAN (sternoclavicular, acromioclavicular, coxofemoral, intratarsal, and metatarsophalangeal) and 160 of non-infectious arthritis diagnosed as such between 2013 and 2016 by microbiological criteria, the presence of crystals or absence of both situations. The explanatory variables were: Three age strata, three CRP levels, three strata of PCT figure, immunomodulation/immunosuppression condition, two strata of time of evolution, the presence of fever and neutrophilia. After a forward modelling, a test validation study was performed using the modelling coefficients as a weight reference for each value of the score. <h3>Results</h3> The only variables that overcame the forward modelling were PCT, temperature, immunosuppression and time of evolution. Using the reference coefficients (table 1), validation tests were performed by means of the ROC curve. According to the presented curve, a sensitivity of 86.6% and specificity of 95.8% is reached if the total score reaches or exceeds 5pts (Strata of PCT 6, 4 and 2, and 2 points by any of the remaining three considerations). The total area under the curve was 0.926. <h3>Conclusions</h3> Taking into account the high specificity achieved, we the authors propose the use of the present score to exclude ASAN in situations in which access to synovial fluid is difficult or technically not feasible. <h3>Disclosure of Interest</h3> None declared
AB1195 Development and validation of an ultrasonographic activity score (USAS) for rheumatoid arthritis
Authors: J.J. De Agustín, A. Erra, A. Ponce, C. Moragues, C. Diaz, P. Moya, D. Reina, P. Estrada, E. Casado, M. Moreno, J. ramirez, L. Mateo, M. Pujol, S. Ros, P. Santo, E.L. Sirvent, J. Narvaez, R. Sanmarti, M. Garcia Yebenes, L. Carmona
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Composite scores developed in Rheumatoid arthritis (RA) not include all dimensions of disease activity. An index based on essential clinical plus a ultrasound (US) measures, focused on simplicity, with appropriate validation, would allow a better classification at different levels of disease activity than a clinical only or US only index. <h3>Objectives</h3> To develop and validate a mixed clinical-US inflammation score in RA for use in clinical practice. <h3>Methods</h3> Mixed methods. Experts elicited items reflecting inflammation which were prioritised by Delphi. Patients with RA with various grades of activity underwent clinical [28 swollen and tender joints counts, patient and physician global assessment (PhGA), erythrocyte sedimentation rate, and C-reactive protein (CRP)] and US assessments [synovitis or tenosynovitis by grey-scale (GS) and Power Doppler (PD) of 42 structures], blinded to the clinical assessment. An index was created after supported selection of US structures and scoring method. Construct validity was tested by correlation with DAS28, SDAI, CDAI, and PhGA. Reliability was evaluated in a subgroup of patients with the intraclass correlation coefficient (ICC). <h3>Results</h3> US of joints and tendons, CRP, and swollen joints were the items that passed the prioritisation phase. Then, 281 patients were randomly divided into design (n=141) and validation analysis (n=140). The combination of US sites chosen detected the maximum proportion of GS and PD present. Were elected wrist, 2–3 MCP, Knee, tibio-talar and 2–3 MTP joints, and the following tendons: carpal extensor and flexor tendons, tibial posterior and peroneal. For scoring structures, three methods were tested: semiquantitative (0–3 GS +0–3 PD), dichotomous (0/1 GS +0/1 PD), and qualitative (0/1 based on algorithm [image 1]). All showed strong correlation with activity measures (rho ≥0.60), and reliability (ICC 0.89 to 0.93). The most feasible index, qualitative, was chosen. The proposed formula for USAS was: <b>USAS=N° swollen joints+US score+CRP</b> <h3>Conclusions</h3> USAS is a valid and reliable measure of inflammation in RA equal to the sum of 28 swollen joint count, a simplified (0/1) US assessment of 11 structures and CRP. <h3>Disclosure of Interest</h3> None declared
Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study
Authors: Paolo Caimi, Deepa Jagadeesh, Kirsten Marie Boughan, Robert M. Dean, Brenda Cooper, Brad Pohlman, Molly M Gallogly, Sarah L. Ondrejka, Erika Moore, Kwadwo Asare Oduro, Eric D. Hsi, Marcos de Lima, Brian T. Hill
Journal: Blood (2018)
SP0089 How to distinguish the major capillaroscopic patterns
Authors: A.L. Herrick
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> The most well-known pattern of capillaroscopic abnormality is the 'systemic sclerosis-pattern', characterised by dilated capillary loops, areas of avascularity, haemorrhages and distortion of the normal nailfold architecture. Cutolo and colleagues have described three patterns within this spectrum: 'early', 'active' and 'late', on the basis of numbers of giant capillaries and of microhaemorrhages, the extent of capillary loss and of disorganisation of the capillary architecture, and the presence of angiogenesis.<sup><sup>1</sup></sup> Systemic sclerosis-pattern abnormalities are also seen in patients with inflammatory muscle disease, especially in those with dermatomyositis, when areas of angiogenesis ('bushy' or 'ramified' capillaries), are very commonly seen. Abnormalities have also been described in other diseases, but these are less specific. This lecture will illustrate the different patterns of abnormality with a focus on systemic sclerosis and inflammatory muscle disease. Capillaroscopic patterns which have been reported in systemic lupus erythematosus, antiphospholipid syndrome, and childhood connective tissue diseases will also be described. <h3>Reference</h3> [1] Cutolo M, Sulli A, Smith V. How to perform and interpret capillaroscopy. Best Practice Res Clin Rheumatol2013; 27:237–48. <h3>Disclosure of Interest</h3> None declared
AB0038 Tbk1: a key regulator and potential treatment target for interferon positive systemic lupus erythematosus and systemic sclerosis
Authors: E. Huijser, I. Bodewes, C. van Helden-Meeuwsen, L. Tas, R. Huizinga, V. Dalm, M. van Hagen, N. Groot, S. Kamphuis, P. van Daele, M. Versnel
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Upregulation of type I interferons (IFN-I) is a hallmark of systemic autoimmune diseases like systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Three different receptor families are implicated in the induction of IFN-I production: Toll-like receptors (TLRs), RIG-like receptors (RLRs) and DNA-sensing receptors (DSRs). TANK-binding kinase (TBK1), is an important signalling hub downstream of RLRs and DSRs. TBK1 activates IRF3 and IRF7, leading to IFN-I production and subsequent induction of interferon-stimulated genes (ISGs). <h3>Objectives</h3> To explore the potential of TBK1 inhibitors to downregulate IFN-I activation in SLE and SSc. <h3>Methods</h3> TBK1, IRF3, IRF7 and STAT1 were determined by qPCR in PAXgene samples and phosphorylated-TBK1 (pTBK1) was analysed by flowcytometry in plasmacytoid dendritic cells (pDCs) from IFN-I positive (IFNpos) patients. Peripheral blood mononuclear cells (PBMCs) from SLE and SSc patients and TLR7-stimulated PBMCs from healthy controls (HCs) were cultured with the TBK1 inhibitors BX795 followed by analysis of ISGs. <h3>Results</h3> Increased expression of TBK1, IRF3, IRF7 and STAT1 in whole blood and pTBK1 in pDCs was observed in IFNpos pSS, SLE and SSc patients compared to HCs. Upon treatment with BX795, PBMCs from IFNpos pSS, SLE, SSc and TLR7-stimulated HCs downregulated the expression of the ISGs MxA, IFI44, IFI44L, IFIT1 and IFIT3. The TBK1 inhibitor inhibited the secretion of IFN-I by TLR7-stimulated PBMCs from HCs. <h3>Conclusions</h3> TBK1 inhibition reduced expression of ISGs in PBMCs from IFNpos SLE and SSc patients patients indicating TBK1 as a potential treatment target. <h3>Acknowledgements</h3> The research for this manuscript was (partly) performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The authors thank patients and healthy volunteers for taking part in this study. <h3>Disclosure of Interest</h3> E. Huijser: None declared, I. Bodewes: None declared, C. van Helden-Meeuwsen: None declared, L. Tas: None declared, R. Huizinga: None declared, V. Dalm: None declared, M. van Hagen: None declared, N. Groot: None declared, S. Kamphuis: None declared, P. van Daele: None declared, M. Versnel Grant/research support from: Research funding Domainex
Mesh implants: women who need corrective surgery have higher risk of depression and self harm, finds study
Authors: Susan Mayor
Journal: BMJ (2019)

Women requiring a surgical intervention for complications following a midurethral mesh sling procedure have significantly increased risk of new onset depression and self harm compared with those not needing corrective procedures, a Canadian population based study1 has found.

Midurethral mesh sling procedures are the standard treatment for stress incontinence in women, but investigations and regulatory warnings about transvaginal mesh complications have led to ongoing concerns about their safety.

The new study analysed routinely collected data from the universal healthcare system in Ontario, Canada, …
THU0238 Ultrasonographic evaluation of distal patellar enthesis in patients affected by entheropatic spondiloarthritis
Authors: A. Batticciotto, G. Prato, M. Antivalle, M.C. Ditto, M. Agosti, E. Cumbo, R. Talotta, F. Atzeni, P. Sarzi-Puttini
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Enteropathic arthritis (EA) belongs to the spondyloarthritis (SpA) spectrum of diseases and occurs in patients affected by inflammatory bowel diseases (IBD). Several works demonstrated that ultrasonography (US) is a feasible, reliable and easily accessible tool for detecting chronic and active entheseal abnormalities even in a subclinical contest in SpA patients.<sup>1,2</sup> <h3>Objectives</h3> To evaluate the prevalence of US entheseal involvement of the distal insertion of patellar ligament in patients affected by EA. <h3>Methods</h3> Twenty-two consecutive AE patients (12 with Crohn's disease and 10 with ulcerative colitis; 8 females and 14 males; mean age 44.7 years, range 18–72 years; mean AE duration 10.1 years range 4–21 years) and 18 healthy age- and gender-matched controls (8 females and 10 males; mean age 48 years, range 24–68 years) underwent an US examination (ESAOTE MyLAB 70 6–18 MHz linear array transducer) according with the validated Madrid Sonographic Enthesis Index (MASEI). Clinical and clinimetric variables were assessed in both groups according with daily clinical practice. <h3>Results</h3> Focusing on the 44 distal patellar entheses we identified a higher prevalence of all the elementary lesion analysed. In 34 entheses we identify a dishomogeneous echostructure (77.3% vs 33.3%; p=0.0001), in 38 structural thickness (86.4% vs 66.7%; p=0.03), in 16 power Doppler positivity (36.3% vs 16.7%; p=0.04), in 17 presence of calcifications (38.6% vs 16.7%; p=0.03) and in 8 entheses the presence of erosions (18.8% vs 0%; p=0.007). In the 45% of the examined patients we detected a simultaneous presence of dishomogeneous echostructure, structural thickness and power Doppler positivity suggestive for US active enthesitis at the level of the same enthesis. <h3>Conclusions</h3> US detectable signs of enthesopathy and enthesitis are very frequent in EA patients even when we analyse the distal enthesis of the patellar ligament alone. Further studies involving a larger number of patients are needed to confirm these preliminary data. <h3>References</h3> [1] Atzeni F, Defendenti C, Ditto MC, et al. "Rheumatic manifestations in inflammatory bowel disease". Autoimmun Rev. 2014Jan;13(1):20–3. [2] Wakefield RJ, Green MJ, Marzo-Ortega H, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis2004;63(4):382–5. <h3>Disclosure of Interest</h3> None declared
Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer
Authors: Yuefeng Wang, Xinhua Yu, Nan Zhao, Jiajing Wang, Chi Lin, Enrique W. Izaguirre, Michael Farmer, Gary Tian, Bradley Somer, Nilesh Dubal, David L. Schwartz, Matthew T. Ballo, Noam A. VanderWalde
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Chemotherapy with or without pelvic radiotherapy (RT) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for metastatic anal cancer (MAC), despite limited clinical evidence for RT in this setting. In addition, increasing evidence shows that local therapies, including RT, may increase patient survival for some types of metastatic cancers. The purpose of this study was to evaluate the patterns of care and association between definitive pelvic RT and overall survival (OS) for patients with MAC. Methods: The National Cancer Database was analyzed to evaluate OS of patients with newly diagnosed MAC treated with chemotherapy with or without pelvic RT. Those who did not undergo treatment, treated with surgery, or without baseline variables were excluded. OS was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards models, and propensity score-matched analyses. Results: From 2004 through 2015, 437 patients received chemotherapy alone and 1,020 received pelvic chemoradiotherapy (CRT). At a median follow-up of 17.3 months, CRT was associated with improved OS on univariate (P<.001) and multivariate analysis (hazard ratio [HR], 0.70; 95% CI, 0.61-0.81; P<.001). Propensity score-matched analysis demonstrated superior median survival (21.3 vs 15.9 months) and 2-year OS rates (46% vs 34%) with CRT compared with chemotherapy alone (P<.001). Landmark analyses limited to long-term survivors of ≥1, ≥2, and ≥4 years showed improved OS with CRT in all subsets (all P<.05). CRT with therapeutic doses (≥45 Gy) was associated with longer median survival than palliative doses (<45 Gy) and chemotherapy alone (24.9 vs 10.9 vs 15.6 months, respectively; P<.001). The benefit of CRT was present among not only those with distant lymph node metastasis (HR, 0.63; P=.04) but also those with distant organ disease (HR, 0.74; P<.001). Conclusions: In this large hypothesis-generating analysis, patients with newly diagnosed MAC who received definitive pelvic RT with chemotherapy lived significantly longer than those who received chemotherapy alone. Prospective trials evaluating definitive local RT for MAC are warranted.
Identification of Target Pathways of Acquired IMiD and Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Mark B. Meads, Paula Oliveira, Bin Fang, Praneeth Sudalagunta, Maria D Coelho Siqueira Silva, Tuan Nguyen, Allison Distler, Salah-Eddin Komrokji, Aunshka Collins, Hongyue Dai, John M. Koomen, Ariosto Siqueira Silva, Kenneth H Shain
Journal: Blood (2017)
AB0205 Comparison of thoracic hrct and self-reported questionnaires in the assessment of pulmonary involvement in rheumatoid arthritis patients: preliminary results
Authors: A. Topcu, Y. Yalcınkaya, S. Karakurt, H.H. Mursaloglu, E. Albayrak, N. Coşkun, M. Demir, E. Dalkılıc, N. İnanç
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Pulmonary involvement in rheumatoid arthritis (RA) is one of the extra-articular manifestations affecting morbidity and mortality during the course of the disease. Pulmonary function tests (PFTs) and thoracic high-resolution computerised tomography (HRCT) are the standard of care in the assessment of pulmonary involvement in RA. In this study, we aimed to compare the findings between self-reported questionnaires and HRCT to detect pulmonary abnormalities in RA patients. <h3>Methods</h3> Forty-two RA patients fulfilling ACR/EULAR classification criteria (2010) who had thoracic HRCT within 6 months of any symptom and/or any pathology on radiography of chest were included in the study. The patients were also assessed by modified Borg Scale, SF-36 Quality of Life Scale and Leicester Cough Questionnaire for the evaluation of respiratory symptoms. <h3>Results</h3> Demographics and clinical characteristics were summarised in table 1. Warrick score, assessing the severity and extent of alveloitis and fibrosis on thoracic HRCT, was evaluated in 15 patients with ILD (score range:4–28). DLCO values were lower in patients with Warrick score ≥1 (73±22% vs. 88±12%, p=0.019) while FVC were not found to be different. The findings of HRCT and self-reported questionnaires were summarised in table 2. Any relationship between self-reported questionnaires and Warrick scores was not detected. Presence of any parenchymal lesions was found to be associated with SF-36 total score (p=0,048). DLCO levels were found to be negatively correlated with SF-36 total scores (r=-0,470, p=0,006). <h3>Conclusions</h3> In this study, we could not show any relationship between self-reported questionnaires and thoracic HRCT findings, except a weak association of the presence of parenchymal lesions with SF-36 scores. Alveolitis and/or fibrosis on thoracic HRCT were found to be associated with lower DLCO. DLCO was shown to be negatively correlated with SF-36 scores. SF-36 might be included in the detection of pulmonary evaluation in RA patients. The relationship between thoracic HRCT findings and self-reported questionnaires in RA necessitates further studies. <h3>Disclosure of Interest</h3> None declared